Tirzepatide shine ci gaba mai karɓar mai karɓar mai karɓa biyu

Gabatarwa

Tirzepatide, wanda Eli Lilly ya kirkira, sabon magani ne na peptide wanda ke wakiltar wani ci gaba a cikin maganin ciwon sukari na 2 da kiba. Ba kamar GLP-1 na gargajiya (glucagon-kamar peptide-1) agonists, Tirzepatide yana aiki akanduka GIP (glucose-dogara insulinotropic polypeptide)kumaGLP-1 masu karɓa, samun shi sunan aDual receptor agonist. Wannan nau'in nau'in nau'in nau'in ciwon sukari na 2 yana ba da damar ingantaccen inganci a cikin daidaita glucose na jini da rage nauyin jiki, musamman ga marasa lafiya da ke da nau'in ciwon sukari na 2 da kiba.

Tsarin Aiki

• Kunna mai karɓar GIP: Yana haɓaka haɓakar insulin kuma yana haɓaka jurewar glucose.

• GLP-1 kunna mai karɓa: Yana inganta sakin insulin, yana hana fitar glucagon, kuma yana rage zubar ciki.

• Dual synergy: Yana ba da ingantaccen sarrafa glycemic da rage nauyi mai mahimmanci.

Binciken Bayanan asibiti

1. Gwajin SURPASS (Nau'in Ciwon sukari na 2)

Gaba ɗayaSURPASS Gwajin asibiti, Tirzepatide ya wuce insulin da Semaglutide a cikin glycemic da sakamakon rage nauyi.

➡ Idan aka kwatanta da Semaglutide (1 MG: HbA1c -1.9%, Weight -6.0 kg), Tirzepatide ya nuna kyakkyawan sakamako a cikin sarrafa glycemic da asarar nauyi.

2. Gwaje-gwajen SURMOUNT (Kiba)

A cikin marasa lafiya masu kiba ba tare da ciwon sukari ba, Tirzepatide ya nuna ingantaccen asarar nauyi.

➡ Ga mara lafiya mai nauyin kilogiram 100, babban adadin Tirzepatide zai iya samun raguwar nauyi a kusa.22.5 kg.

Mabuɗin Amfani

1. Hanya biyu: Bayan guda GLP-1 agonists.

2. Babban inganci: Mai tasiri a cikin sarrafa glycemic da sarrafa nauyi.

3. Faɗin zartarwa: Ya dace da ciwon sukari da kuma kiba.

4. Babban kasuwa m: Haɓakar buƙatu don matsayi na kula da kiba Tirzepatide a matsayin maganin toshewar gaba.

Kasuwa Outlook

• Hasashen girman kasuwa: Nan da 2030, ana hasashen kasuwar magunguna ta GLP-1 ta duniya za ta wuceDalar Amurka biliyan 150, tare da Tirzepatide mai yuwuwar kama babban rabo.

• Gasar shimfidar wuriBabban abokin hamayyar shine Novo Nordisk's Semaglutide (Ozempic, Wegovy).

• Amfani: Bayanan asibiti sun nuna Tirzepatide yana ba da asarar nauyi mafi girma idan aka kwatanta da Semaglutide, yana ƙarfafa gasa ta kasuwa a cikin maganin kiba.